Display options
Cite
King D, Southgate HED, Roetschke S, et al. Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246215.
King, D., Southgate, H. E. D., Roetschke, S., Gravells, P., Fields, L., Watson, J. B., Chen, L., Chapman, D., Harrison, D., Yeomanson, D., Curtin, N. J., Tweddle, D. A., & Bryant, H. E. (2021). Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers, 13(24), . https://doi.org/10.3390/cancers13246215
King, David, et al. "Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246215
King D, Southgate HED, Roetschke S, Gravells P, Fields L, Watson JB, Chen L, Chapman D, Harrison D, Yeomanson D, Curtin NJ, Tweddle DA, Bryant HE. Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers (Basel). 2021 Dec 10;13(24). doi: 10.3390/cancers13246215. PMID: 34944835; PMCID: PMC8699051.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Dec 10;13(24). doi: 10.3390/cancers13246215.

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells.

Cancers

David King, Harriet E D Southgate, Saskia Roetschke, Polly Gravells, Leona Fields, Jessica B Watson, Lindi Chen, Devon Chapman, Daniel Harrison, Daniel Yeomanson, Nicola J Curtin, Deborah A Tweddle, Helen E Bryant

Affiliations

  1. Academic Unit of Molecular Oncology, Department of Oncology and Metabolism, Sheffield Institute for Nucleic Acids (SInFoNiA), University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK.
  2. Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
  3. Newcastle Centre for Cancer, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
  4. Sheffield Children's Hospital, Western Bank, Sheffield S10 2TH, UK.

PMID: 34944835 PMCID: PMC8699051 DOI: 10.3390/cancers13246215

Abstract

Despite intensive high-dose multimodal therapy, high-risk neuroblastoma (NB) confers a less than 50% survival rate. This study investigates the role of replication stress in sensitivity to inhibition of Ataxia telangiectasia and Rad3-related (ATR) in pre-clinical models of high-risk NB. Amplification of the oncogene

Keywords: ATR; MYCN; PARP; neuroblastoma; replication stress

References

  1. Oncogene. 1996 Aug 15;13(4):803-12 - PubMed
  2. N Engl J Med. 1985 Oct 31;313(18):1111-6 - PubMed
  3. EBioMedicine. 2015 Nov 10;2(12):1923-31 - PubMed
  4. Annu Rev Genet. 2016 Nov 23;50:155-173 - PubMed
  5. Crit Rev Oncol Hematol. 2016 Dec;108:73-85 - PubMed
  6. Clin Cancer Res. 2017 Aug 1;23(15):4354-4363 - PubMed
  7. Mol Cell. 2006 Aug 4;23(3):331-41 - PubMed
  8. Open Biol. 2019 Aug 30;9(8):190136 - PubMed
  9. Cancer Res. 2013 Jan 15;73(2):776-84 - PubMed
  10. N Engl J Med. 2010 Jun 10;362(23):2202-11 - PubMed
  11. Nat Commun. 2020 Feb 14;11(1):913 - PubMed
  12. Cancers (Basel). 2020 Apr 28;12(5): - PubMed
  13. Br J Cancer. 2016 Oct 25;115(9):1048-1057 - PubMed
  14. Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27 - PubMed
  15. Oncotarget. 2020 Jun 09;11(23):2141-2159 - PubMed
  16. J Clin Oncol. 2009 Jan 10;27(2):289-97 - PubMed
  17. Science. 1984 Jun 8;224(4653):1121-4 - PubMed
  18. EMBO J. 2009 Sep 2;28(17):2601-15 - PubMed
  19. Clin Cancer Res. 2009 Feb 15;15(4):1241-9 - PubMed
  20. Oncogene. 2017 Aug 17;36(33):4682-4691 - PubMed
  21. Genes Dev. 2008 Oct 15;22(20):2755-66 - PubMed
  22. Nat Rev Mol Cell Biol. 2017 Oct;18(10):622-636 - PubMed
  23. Nat Rev Cancer. 2015 May;15(5):276-89 - PubMed
  24. Nat Commun. 2018 Feb 21;9(1):746 - PubMed
  25. Cell Rep. 2019 Oct 15;29(3):551-559.e4 - PubMed
  26. J Natl Cancer Inst. 2017 Nov 1;109(11): - PubMed
  27. Clin Cancer Res. 2015 Nov 1;21(21):4780-5 - PubMed
  28. Hum Mol Genet. 2014 Dec 20;23(25):6826-37 - PubMed
  29. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3336-41 - PubMed
  30. Int J Mol Sci. 2021 Jun 08;22(12): - PubMed
  31. Biochim Biophys Acta. 2015 May;1849(5):517-24 - PubMed
  32. Nat Commun. 2017 Nov 9;8(1):1392 - PubMed
  33. Nat Commun. 2020 Jul 24;11(1):3726 - PubMed
  34. Front Oncol. 2015 May 13;4:330 - PubMed
  35. J Cell Biol. 2015 Mar 2;208(5):563-79 - PubMed
  36. Cancer Res. 2012 Jun 1;72(11):2814-21 - PubMed
  37. Mol Cell Biol. 2005 Aug;25(16):7158-69 - PubMed
  38. EBioMedicine. 2020 Sep;59:102971 - PubMed
  39. Pediatr Blood Cancer. 2013 Jun;60(6):985-93 - PubMed
  40. Nat Cell Biol. 2014 Jan;16(1):2-9 - PubMed
  41. Mol Cell. 2010 Feb 26;37(4):492-502 - PubMed
  42. Clin Cancer Res. 2017 Nov 15;23(22):6875-6887 - PubMed

Publication Types

Grant support